BioSpace News Archive

Indivior PLC announced its financial results for the period ending June 30, 2023.

Takeda announced strong financial results for the first quarter of fiscal year 2023. Takeda chief financial officer, Costa Saroukos, commented: “Our Growth & Launch Products continued to drive revenue growth in the first quarter of FY2023, contributing to a core operating profit margin of 30.8%.

Topline results from the primary analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed ENHERTU® demonstrated clinically meaningful progression-free survival and overall survival in previously treated patients across multiple HER2 expressing advanced solid tumors, two secondary endpoints of the trial.

Annexon, Inc. announced the appointment of Jamie Dananberg, M.D., as chief medical officer.

Lipocine Inc., a biopharmaceutical company focused on treating Central Nervous System disorders by leveraging its proprietary platform to develop differentiated products, announced positive topline results from a Phase 2 clinical study of LPCN 1148.

West Pharmaceutical Services, Inc. announced its financial results for the second-quarter 2023 and updated full-year 2023 financial guidance.

Ipsen, a global specialty-care biopharmaceutical company, presents its financial results for the first half of 2023.

Galderma maintained strong momentum across all product categories reaching 2,003 M USD net sales in H1 2023, up 6.9% year-on-year on a constant currency basis.

Sientra, Inc., a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023.

Immunic, Inc. announced that the company will release its financial results for the second quarter ended June 30, 2023, including a corporate update, on Thursday, August 3, 2023, before the opening of the U.S. financial markets.